

# Resource Summary Report

Generated by [RRID](#) on Aug 14, 2026

## DC-SIGN antibody [5D7]

RRID:AB\_940866

Type: Antibody

### Proper Citation

Abcam Cat# ab59192, RRID:AB\_940866

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_940866](http://antibodyregistry.org/AB_940866)

**Proper Citation:** Abcam Cat# ab59192, RRID:AB\_940866

**Target Antigen:** DC-SIGN antibody [5D7]

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** validation status unknown, seller recommendations provided in 2012: IHC-FoFr, IHC-P, WB; Immunohistochemistry; Immunohistochemistry - frozen; Western Blot; Immunohistochemistry - fixed

**Antibody Name:** DC-SIGN antibody [5D7]

**Description:** This monoclonal targets DC-SIGN antibody [5D7]

**Target Organism:** human

**Antibody ID:** AB\_940866

**Vendor:** Abcam

**Catalog Number:** ab59192

**Record Creation Time:** 20250819T210234+0000

**Record Last Update:** 20250819T213930+0000

### Ratings and Alerts

No rating or validation information has been found for DC-SIGN antibody [5D7].

No alerts have been found for DC-SIGN antibody [5D7].

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Chaudhary R, et al. (2025) Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research.

Wu RQ, et al. (2023) Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma. Immunity, 56(1), 180.